Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Other Rheumatic Conditions

Secukinumab Effective for Psoriatic Arthritis

Lara C. Pullen, PhD  |  October 12, 2015

A Phase 3 study found secukinumab may be an effective alternative to anti-TNF therapies for treating psoriatic arthritis, suggesting interleukin 17A may play a role in the disease…

Treating IBD with Anti-TNF Tied to Higher Risk of Demyelinating Disease

Will Boggs, MD  |  October 9, 2015

NEW YORK (Reuters Health)—Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors is associated with a doubling of the risk of central nervous system demyelinating disease, researchers from Denmark report. “Based on the current evidence anti-TNF should be used cautiously in patients with an own or family history of demyelinating disease,” Dr. Nynne…

Psoriasis Tied to Increased Risk of Major Depression

Will Boggs, MD  |  October 8, 2015

NEW YORK (Reuters Health)—People with psoriasis are twice as likely as others to have major depression, according to data from the National Health and Nutrition Examination Survey (NHANES). In earlier work, psoriasis has been linked to depression, anxiety and substance abuse. Studies have shown that both depression and psoriasis are associated with cardiovascular disease, which…

Immunotherapy May Be Effective for Some Patients with Autoimmune Cerebellar Ataxia

Will Boggs, MD  |  October 7, 2015

NEW YORK (Reuters Health)—Immunotherapy appears to yield neurological improvements in some patients with autoimmune cerebellar ataxia, especially those with nonparaneoplastic disorders, researchers report. “I was surprised that so many patients responded to immunotherapy (steroids, intravenous immunoglobulin (IVIg), and plasma exchange) and remained ambulatory,” Dr. Andrew McKeon from Mayo Clinic in Rochester, Minn., told Reuters Health…

Patients with Psoriasis, Psoriatic Arthritis at Increased Risk of Migraine

Shannon Aymes  |  October 4, 2015

NEW YORK (Reuters Health)—Psoriasis and psoriatic arthritis are associated with an increased risk of migraine, according to new research from Denmark. “The main finding of our study was a psoriasis severity-dependent increased risk of new-onset migraine, and patients with severe skin psoriasis and psoriatic arthritis appeared to have the highest risk,” Dr. Alexander Egeberg from…

Relapse Rates High in IBD Patients who Stop Treatment

Megan Brooks  |  September 28, 2015

NEW YORK (Reuters Health)—Inflammatory bowel disease (IBD) patients who achieve remission on treatment may want to go off their IBD medications. But half or more of those who do will have a relapse, according to comprehensive analysis of relevant research. “Based on the studies with extended periods of follow up, relapse rates after cessation appear…

IBD Tied to Higher Risk of Invasive Pneumococcal Disease

David Douglas  |  September 24, 2015

NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) are at slightly increased risk of invasive pneumococcal disease (IPD), according to Danish researchers. In a paper online Sept. 8 in The American Journal of Gastroenterology, Bjørn Kantsø of Statens Serum Institut in Copenhagen and colleagues note that the inappropriate immune response against infective agents seen in…

POP1-Based Treatments May Reduce Inflammation

Lara C. Pullen, PhD  |  September 21, 2015

A recent study analyzed inflammasome response, finding the POP1 PYRIN domain protein acts to decrease excessive inflammatory responses and prevent systemic inflammation. Researchers ultimately developed a drug based on POP1 and found it reduced inflammation in mice…

Diagnosing, Treating IgG4-Related Disease

Mary Beth Nierengarten  |  September 15, 2015

In diagnosing and treating a disease that is rapidly gaining recognition worldwide since it was first recognized in Japan in 2003, 42 experts from 10 different countries recently collaborated to discuss and review the current experience and data on IgG4-related disease. The result is the “International Consensus Guidance Statement on the Management and Treatment of…

Project Increases Pneumococcal Vaccination Rates in Rheumatology Patients

Will Boggs, MD  |  August 26, 2015

NEW YORK (Reuters Health)—A multicomponent intervention can significantly increase pneumococcal vaccination rates in pediatric rheumatology patients, researchers report. “The interventions outlined in our article can easily be implemented in pediatric rheumatology practices or other subspecialty clinics,” Dr. Julia G. Harris from Children’s Mercy Hospital, Kansas City, Mo., told Reuters Health by email. “It takes additional…

  • « Previous Page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • …
  • 35
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences